An evaluation of off-label use of recombinant activated human factor VII (NovoSeven): Patient characteristics, utilization trends, and outcomes from an electronic database of U.S. academic health centers

P and T

Volumn 32, Issue 4, 2007, Pages

  Magnetti, Sandra ^b   Oinonen, Michael ^a   Matuszewski, Karl A ^a  

^a University Health System Consortium ^*  (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

CLINICAL TRIAL; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HUMAN; OFF LABEL DRUG USE; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME;

EID: 34248369800     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. NovoSeven, package insert. Princeton, NJ: Novo Nordisk Inc.; 2005.
2. Kessler CM. New products for managing inhibitors to coagulation factors: A focus on recombinant factor VIIa concentrate. Curr Opin Hematol 2000;7:408-413.
3. Drug Topics Red Book. Montvale, NJ: Thomson Medical Economics; 2005. October 2005 update.
4. Shander A, Goodnough LT, Ratko T, et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven) therapy. P&T 2005;30:644-658.
5. Blatt J, Gold SH, Wiley JM, et al. Off-label use of recombinant factor Vila in patients following bone marrow transplantation. Bone Marrow Transplant 2001;28:405-407.
6. MacLaren R, Weber LA, Brake H, et al. A multicenter assessment of recombinant factor VIIa off-label usage: Clinical experiences and associated outcomes. Transfusion 2005;45:1434-1442.
7. Goodnough LT, Lublin DM, Zhang L, et al. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004;44:1325-1331.
8. Ghorashian S, Hunt BJ. "Off-license" use of recombinant activated factor VII. Blood Rev 2004;18:245-259.
9. Carr ME Jr, Martin EJ. Recombinant factor VIIa: Clinical applications for an intravenous hemostatic agent with broad-spectrum potential. Exp Rev Cardiovasc Ther 2004;2:661-674.
10. Greisen G, Andreasen RB. Recombinant factor VIIa in preterm neonates with prolonged prothrombin time. Blood Coagul Fibrinol 2003;14:117-120.
11. Jeffers L, Chalasani N, Balart L, et al. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 2002;123:118-126.
12. Friederich PW, Wever PC, Briet E, et al. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol 2001;66:292-294.
13. Dutton RP, Hess JR, Scalea TM. Recombinant factor VIIa for control of hemorrhage: Early experience in critically ill trauma patients. J Clin Anesth 2003;15:184-188.
14. Mindikoglu AL, Anantharaju A, George M, et al. Acute intracranial hemorrhage in a cirrhotic controlled with recombinant factor VIIa. Dig Dis Sci 2003;48:1130-1135.
15. Deveras RA, Kessler C. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002;137:884-888.
16. Hunault M, Bauer KA. Recombinant factor VIIa for the treatment of congenital factor VII deficiency. Semin Thromb Hemost 2000; 26:401-405.
17. O'Connell NM. Factor XI deficiency. Semin Hematol 2004;41 (1 Suppl 1):76-81.
18. Flynn JD, Camp PC Jr, Jahania MS, et al. Successful treatment of refractory bleeding after bridging from acute to chronic left ventricular assist device support with recombinant activated factor VII. ASAIO J 2004;50:519-521.
19. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: Two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005;59:8-18.
20. Bijsterveld NR, Vink R, van Aken BE, et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004;124(5):653-658.
21. Bosch J, Thabut D, Bendtsen F, et al., and the European Study Group on rFVIIa in Upper GI Hemorrhage. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: A randomized, double-blind trial. Gastroenterology 2004; 127:1123-1130.
22. Mayer SA, Brun NC, Begtrup K, et al., and the Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777-785.
23. Ratko T, Cummings JP, Matuszewski KA. Off-label use of recombinant activated factor VII (NovoSeven). P&T 2004;29: 712-720.
24. Martinowitz U, Michaelson M, and the Israeli Multidisciplinary rFVIIa Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding. J Thromb Haemost 2005;3:640-648.
25. Enomoto TM, Thorborg P. Emerging off-label uses for recombinant activated factor VII: Grading the evidence. Crit Care Clin 2005;21:611-632.
26. van het Loo M, Kahan JP. The RAND Appropriateness Method: An Annotated Bibliography Through June 1999. Leiden, The Netherlands: RAND Europe; 1999.
27. Fitch K, Bernstein S, Aguilar MD, et al. The RAND/UCLA Appropriateness Method User's Manual. Santa Monica, CA: RAND Institute; 2001.
28. Shekelle PG, Kahan JP, Bernstein SJ, et al. The reproducibility of a method to identify the overuse and underuse of medical procedures. N Engl J Med 1998;338:1888-1895.